Humanitas Approved by American Psychological Association (APA) as Provider of Continuing Education Credits to Psy...(opez Schell mary.schell@ .....),Health
Navigation Links
Humanitas Approved by American Psychological Association (APA) as Provider of Continuing Education Credits to Psychologists
Date:4/8/2009
opez Schell mary.schell@humanitas.com (301) 608-3290 EXT. 313
'/>"/>
| SOURCE Humanitas, Inc. Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. $52.5 Million Settlement Against Sepracor Inc. Approved
2. FDA Cracks Down on Unapproved Cough Medicines
3. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
4. Optometry-Backed Vision Care for Kids Act Approved by U.S. House
5. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
6. A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks
7. Barrs Generic Version of Estrostep(R) Fe Tablets Approved
8. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
9. Pennsylvania American Waters Rate Case Approved
10. RNs Statement on Death of Nataline Sarkisyan: CIGNA Should Have Listened to her Doctors and Approved the Transplant a Week Ago
11. Hiemstra Approved to Manufacture Medical Devices in New CER
Post Your Comments:
(Date:3/13/2010)... say , , SATURDAY, March 13 (HealthDay News) -- Running ... shows that the performance of female marathoners can be ... Researchers analyzed marathon race results, weather data and air ... period of eight to 28 years. They found that ... slower finish times for women. Air pollution levels didn,t ...
(Date:3/13/2010)... participants. , ... (PRWEB) March 13, 2010 -- The ... announced the success of the ASMBS Foundation and Obesity Action Coalition’s ... American Society for Metabolic and Bariatric Surgery (ASMBS) Foundation, San Antonio’s ... walkers and was the #3 fundraising event nationally., , ,During the ...
(Date:3/13/2010)... Resource Center with information about a variety of legal and practical ... ... March 13, 2010 -- Morgan and Morgan is pleased ... its website, ForThePeople.com. A collection of legal articles, videos, news, resources, ... Morgan and Morgan to provide women with easy access to information ...
(Date:3/13/2010)... Orthopaedic Society for Sports Medicine,s (AOSSM) Specialty Day in ... skeletally mature high school pitchers were satisfied with their ... percent) returned to competitive baseball. , "Tommy John" ... (ulnar collateral ligament or UCL) is replaced with a ... named for Hall of Fame pitcher Tommy John, who ...
(Date:3/12/2010)... Persistent back pain can be absolutely unbearable. ... with a person,s enjoyment of life; from sports and ... is a critical key to remaining mobile. For people ... with little or no result, Orthopedic Spine Surgery ... surgery can provide relief from back pain for a ...
Breaking Medicine News(10 mins):Health News:Air Pollution Slows Women's Marathon Times 2Health News:BMI of Texas Hosts Successful 2009 Walk from Obesity 2Health News:BMI of Texas Hosts Successful 2009 Walk from Obesity 3Health News:Morgan and Morgan Announces Release of New Women's Legal Resource Center 2Health News:Morgan and Morgan Announces Release of New Women's Legal Resource Center 3Health News:'Tommy John' elbow reconstruction 95 percent successful with grown teen pitchers, study says 2Health News:World Renowned Los Angeles Surgeon Pioneers Alternative Orthopedic Spine Surgery 2[0] Air Pollution Slows Women's Marathon Times[0] BMI of Texas Hosts Successful 2009 Walk from Obesity[0] Morgan and Morgan Announces Release of New Women's Legal Resource Center[0] 'Tommy John' elbow reconstruction 95 percent successful with grown teen pitchers, study says[0] World Renowned Los Angeles Surgeon Pioneers Alternative Orthopedic Spine Surgery
... be life-threatening to newborns , , THURSDAY, May 22 (HealthDay ... severe coxsackievirus infections in infants in the United States ... B1 (CVB1) is a form of enterovirus, which usually ... in newborns. , According to the Nemours Foundation, outbreaks ...
... Over 800 Physicians, DALLAS, May 22 ... in hosted services for email encryption and,e-prescribing, today ... plan, will be offering the Company,s PocketScript(R) e-Prescribing,Service ... is one of,several vendors that will be available ...
... of today,s,congressional subcommittee hearing on animal-disease research on ... should serve several,purposes:, * Underscore the critical ... real and present threat of diseases that could,harm ... * Demonstrate the urgency of addressing foreign-animal diseases, ...
... Case Management Society of America to Sponsor MEP Workshop at Annual ... ... Ohio, May 22 The Population Health Impact,Institute (PHII), a non-profit ... the draft Methods Evaluation,Process(TM) (MEP(TM)) Accreditation Standards. The comment period ends ...
... Americans whove received drug-eluting stents to open their blocked ... research from the University of Pennsylvania School of Medicine. ... to show a clear, lifesaving benefit of drug-eluting stents ... the May 27 issue of the Journal of the ...
... May 22 /Xinhua-PRNewswire/ -- Chindex International,(Nasdaq: CHDX ... named as a,finalist for the Ernst & Young ... Washington Region. According to Ernst & Young LLP, ... in,the areas of innovation, financial performance and personal ...
Other Medicine News:Health News:Coxsackievirus Infections Spiked in 2007: CDC 2Health News:L.A. Care Offers ZixCorp e-Prescribing Services Through Health I.T. Incentive Program 2Health News:L.A. Care Offers ZixCorp e-Prescribing Services Through Health I.T. Incentive Program 3Health News:Tip Sheet: Kansas Responds to Congressional Hearing on Animal Disease Research 2Health News:Population Health Impact Institute Releases Methods Evaluation Process(TM) (MEP(TM)) Accreditation Standards for Public Comment Period 2Health News:More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures 2Health News:Chindex International, CEO, Roberta Lipson Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Finalist in Greater Washington 2Health News:Chindex International, CEO, Roberta Lipson Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Finalist in Greater Washington 3Coxsackievirus Infections Spiked in 2007: CDCL.A. Care Offers ZixCorp e-Prescribing Services Through Health I.T. Incentive ProgramTip Sheet: Kansas Responds to Congressional Hearing on Animal Disease ResearchPopulation Health Impact Institute Releases Methods Evaluation Process(TM) (MEP(TM)) Accreditation Standards for Public Comment PeriodMore patients with drug-coated cardiac stents survive, avoid costly follow-up proceduresChindex International, CEO, Roberta Lipson Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Finalist in Greater Washington
(Date:3/11/2010)... The U.S. Food and Drug ... new drug application (sNDA) of a new six-month ... Depot (leuprolide acetate for depot ... advanced prostate cancer. Palliative treatment helps to relieve ... works by suppressing the production of the hormone ...
(Date:3/11/2010)... N.J. , March 11 ... today announced the U.S. Food and Drug Administration ... for injectable suspension), a new twice-yearly formulation of ... of advanced prostate cancer. With an anticipated May ... only six-month intramuscular (IM) GnRH agonist available for ...
(Date:3/11/2010)... 11 Bone Biologics, Inc. announced ... Office Notice of Allowance of patent claims which ... purifying the NELL-1 sequence of the UCB-1 recombinant ... Chinese hamster ovary (CHO) cell. This patent continues ... applications of manufacturing and use in bone regeneration ...
Breaking Medicine Technology:Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 2Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 3Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 4Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 5Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 6Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process 2Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process 3Former Senate Majority Leaders Baker Daschle and Dole Commend Senate Passage of Health Care Bill 63888 1Former Senate Majority Leaders Baker Daschle and Dole Commend Senate Passage of Health Care Bill 63888 2Former Senate Majority Leaders Baker Daschle and Dole Commend Senate Passage of Health Care Bill 63888 3Bunge Limited to Expand Sugar and Bioenergy Business in Brazil 15260 1Bunge Limited to Expand Sugar and Bioenergy Business in Brazil 15260 2Bunge Limited to Expand Sugar and Bioenergy Business in Brazil 15260 3Bunge Limited to Expand Sugar and Bioenergy Business in Brazil 15260 4Bunge Limited to Expand Sugar and Bioenergy Business in Brazil 15260 5Research Reveals How Breast Cancer Rearranges Genome 63884 1Research Reveals How Breast Cancer Rearranges Genome 63884 2[0] Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer[0] FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer[0] Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process
... for Treatment of AllergySAN DIEGO , April 16 ... the development of novel Toll-Like Receptor 8 (TLR8) agonists ... announced today that it has initiated a Phase I ... for the treatment of allergic rhinitis. The objectives of ...
... of Newly Diagnosed Patients Receive a Drug Within One ... Report from Decision ResourcesWALTHAM, Mass., April 15 ... world,s leading research and advisory firms focusing on pharmaceutical ... less than 30 percent of their use of emerging ...
Other Medicine Technology:VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis 2Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line 2Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line 3... Medicomps revolutionary technology provides full picture ... monitor to incorporate true Artifi cial Intelligence, ... real-time capacity, in the background, on each ... patients cardiac activity based on rate, rhythm, ...
... Designed specifically to ... interventionalists, Sequitor facilitates the ... the peripheral vasculature for ... both uterine fibroid embolization ...
Reference Lab Interface (RLI)© for SRS Software, provides real-time processing of HL7 lab data directly into SRS Freedom Chart ManagerTM, producing an HTML form in the patients chart/tab, whil...
... Continuing a long history of technology ... system is a seventh-generation device on the ... vessel harvesting system improves on a familiar ... technology. Guidant builds new flexibility and finesse ...
Medicine Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |